DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.65
-0.10 (-1.48%)
At close: Aug 10, 2026, 4:00 PM EDT
6.73
+0.08 (1.27%)
After-hours: Aug 10, 2026, 7:34 PM EDT
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,072,600
Market Cap
358.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsDMAC News
- Just now - DiaMedica Therapeutics Earnings release: Q2 2026 - Filings
- Just now - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings
- 5 hours ago - DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c) - TheFly
- 5 hours ago - DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 6 days ago - DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
- 24 days ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 6 weeks ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire